In what patient subsets (RA biomarkers, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective?

In what patient subsets (RA biomarkers, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective?

In what patient subsets (RA biomarker subsets, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective? Do they seem to optimize outcomes when they are used earlier in the natural history of the disease?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Daniel Furst, MD

Daniel Furst, MD

Professor of Rheumatology
Carl M. Pearson Chair of Rheumatology
Director of Interventional Therapeutics
University of California, Los Angeles Medical Center for Health Sciences
Los Angeles, CA